Company: KROS
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001664710-25-000018
Chunk: 199

Company: Keros Therapeutics, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 199
---
 weighted-average grant date fair value per share of options granted during each of the years ended December 31, 2024, 2023, and 2022 was $40.92, $35.24 and $31.18, respectively. As of December 31, 2024, there was $82.0 million of unrecognized stock-based compensation expense related to unvested stock options, including 4.9 million of unrecognized stock-based compensation expense related to unvested performance-based stock options. The unrecognized stock-based compensation expense is estimated to be recognized over a period of 2.49 years.  

F-18

Stock-Based Compensation ExpenseTotal stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December 31, 2024, 2023 and 2022 is as follows (in thousands):YEAR ENDED DECEMBER 31,202420232022Research and development$18,294 $14,082 $8,205 General and administrative16,578 14,681 10,477 Total stock-based compensation expense$34,872 $28,763 $18,682 

10. INCOME TAXES

Loss before income taxes for the years ended December 31, 2024, 2023 and 2022 consisted of the following (in thousands):YEAR ENDED DECEMBER 31,202420232022United States$(189,315)$(156,571)$(112,240)Foreign2,262 3,579 7,561 Loss before income taxes$(187,053)$(152,992)$(104,679)The components of the provision for income taxes for the years ended December 31, 2024, 2023 and 2022 consisted of the following (in thousands):YEAR ENDED DECEMBER 31,202420232022Current income tax provision:Federal$— $— $— State— — — Foreign300 — — Total current income tax provision$300 $— $— Total deferred income tax provision$— $— $— Total income tax provision$300 $— $— A reconciliation of the Company’s statutory income tax rate to the Company’s effective income tax rate for the years ended December 31, 2024, 2023 and 2022 was as follows